Trophos
| Company type | Private |
|---|---|
| Industry | Biopharmaceutical |
| Founded | 1999 in Marseille, France |
| Founder | Christopher Henderson, Olivier Pourquie, Jean-Louis Kraus, Antoine Beret, Michel Delaage |
| Defunct | 2015 |
| Fate | Acquired by Hoffmann-La Roche |
| Headquarters | Marseille , France |
| Products | Olesoxime (TRO19622) |
Trophos was a biopharmaceutical firm dedicated to the research and development of innovative treatments targeting rare neurodegenerative conditions as well as more prevalent diseases.
Established in 1999 in Marseille by a team comprising scientists Christopher Henderson, Olivier Pourquie, Jean-Louis Kraus, alongside entrepreneurs Antoine Beret and Michel Delaage, the company’s primary drug candidate was olesoxime (TRO19622), designed to act on mitochondria for the treatment of neurodegenerative disorders.
In January 2015, Hoffmann-La Roche revealed its intention to acquire Trophos, offering an initial payment plus additional milestone-based compensation. The transaction was finalized shortly after the announcement.